March 19, 2026
On November 12, 2025, President Trump signed H.R. 5371, the Continuing Appropriations Act, into law. Buried in Section 781 was a provision that will reshape the hemp industry more fundamentally than any federal action since the 2018 Farm Bill. The provision narrows the federal definition of hemp and sets a one-year implementation window that expires on November 12, 2026. For operators in the hemp-derived cannabinoid space, that deadline is not theoretical. It is the date on which products currently sitting on shelves may become Schedule I controlled substances.
Informational only. This content is not legal or tax advice.
The 2018 Farm Bill defined hemp as cannabis with a delta-9 THC concentration of not more than 0.3 percent on a dry weight basis. That definition, codified in the Agricultural Marketing Act, created the legal foundation for the entire hemp-derived cannabinoid market: CBD products, delta-8 THC, delta-10 THC, HHC, THCa flower, and a range of other products that could claim legal status under the hemp umbrella.
Section 781 narrows that definition. The specific changes target intoxicating hemp-derived products by adjusting the cannabinoid thresholds and product classifications that determine whether a product qualifies as hemp or falls under the Controlled Substances Act.
The mechanism is structural and automatic. Because the CSA excludes "hemp" by cross-referencing the Agricultural Marketing Act definition, any narrowing of that definition pushes products back into CSA Schedule I without requiring separate DEA rulemaking. There is no comment period, no administrative review, and no gradual phase-in beyond the one-year implementation window already set by the statute.
As Arnold and Porter noted in December 2025, the change effectively reclassifies many hemp-derived intoxicating THC products as controlled substances once the effective date arrives.
Section 781 also directed the FDA to publish a list of known cannabinoids within 90 days of enactment. That deadline was February 2026. The FDA missed it.
The missed deadline is significant for two reasons. First, the cannabinoid list would provide clarity on exactly which compounds are affected by the narrowed definition. Without it, operators face ambiguity about whether specific products in their portfolio fall inside or outside the new boundary. Second, the FDA's delay suggests the agency is struggling with the technical and political complexity of cataloging cannabinoids in a way that has regulatory force.
More recently, in March 2026, the FDA submitted a CBD Products Compliance and Enforcement Policy to the Office of Management and Budget for review. Once finalized, this enforcement policy will likely be the primary guidance document for operators navigating the transition. Its contents are not yet public, but the fact that it exists suggests the FDA intends to establish a compliance framework rather than rely on enforcement discretion alone.
Any operator in the hemp-derived cannabinoid space needs to assess their product portfolio against the narrowed definition. The categories most directly affected include:
Delta-8 THC products. These have been the most commercially visible hemp-derived intoxicating products and have already faced state-level restrictions in multiple jurisdictions. The federal definition change would add a federal prohibition layer on top of existing state rules.
Delta-10 THC and HHC products. Similar to delta-8, these cannabinoids gained market traction by operating in the space between the 2018 Farm Bill's hemp definition and the CSA. The narrowed definition closes that space.
THCa flower. Products marketed as hemp flower with high THCa concentrations that convert to delta-9 THC when heated occupy an especially precarious position under the new rules, depending on how total THC is calculated in the revised definition.
High-potency CBD products with trace THC. While most standard CBD products are unlikely to be affected, operators should verify that their formulations and testing protocols account for any changes in how THC thresholds are measured or calculated under the new definition.
As Frier Levitt's March 2026 analysis explained, the redefinition creates a compliance complexity that extends beyond product formulation to labeling, marketing claims, and distribution agreements.
The product-level risk is only the starting point. The narrowed definition cascades through supply chains in ways that operators should map now, before November.
Ingredient suppliers providing hemp-derived cannabinoid extracts will need to certify that their materials meet the new definition. Existing supply agreements may not contain representations specific enough to cover the revised thresholds. Operators should review supplier contracts for cannabinoid specification clauses and determine whether amendments are needed.
Distribution partners, particularly those in states where intoxicating hemp products are currently legal, face their own compliance assessments. Retail partners may begin pulling products preemptively if they lack confidence in the product's legal status after November 2026. Early communication with distribution and retail partners about your compliance roadmap reduces the risk of sudden delistings.
Payment processors and banking partners already treat hemp-derived THC products with caution. A federal reclassification to Schedule I would likely trigger immediate account reviews or terminations for operators whose product lines fall outside the new hemp definition.
The eight months remaining before the effective date are a planning window, not a waiting period. Operators who use this time to assess, adjust, and document their compliance position will be better positioned than those who wait for final FDA guidance that may arrive late or not at all.
Map every SKU against the narrowed hemp definition. For each product, document the cannabinoid profile, the source material specifications, and the testing methodology used to verify compliance. Identify which products clearly meet the new definition, which clearly do not, and which fall in a gray area that depends on how the FDA and DEA interpret specific provisions.
For gray-area products, develop contingency plans: reformulation options, alternative sourcing, or product discontinuation timelines. The goal is to have a decision framework ready before November rather than reacting to enforcement actions after.
If the narrowed definition changes how THC thresholds are measured, whether by total THC calculation, post-decarboxylation adjustments, or cannabinoid-specific limits, your testing protocols need to align with the new methodology. Engage your testing laboratory now to understand whether their current panels and reporting formats will satisfy the revised requirements.
Certificates of analysis generated under the old definition may not provide adequate documentation under the new one. Establish a cutover plan for testing and documentation that ensures every product on the market after November has supporting lab work aligned to the current legal standard.
The federal definition change does not override state laws that are more permissive or more restrictive. Some states have already banned delta-8 and similar products regardless of federal hemp status. Others have established their own regulatory frameworks for intoxicating hemp products that may continue to operate independently of the federal change.
Operators in states with active hemp-derived THC programs should monitor whether those states adjust their own definitions to align with the federal change, maintain independent frameworks, or create transitional rules for products already in commerce.
Existing contracts with suppliers, distributors, retailers, and white-label partners may contain terms that reference the current hemp definition or assume the legal status of specific products. If those products are reclassified, force majeure clauses, termination rights, and indemnification provisions become relevant.
A contract review focused specifically on hemp definition dependencies is a targeted, manageable exercise that can prevent expensive disputes later. Prioritize agreements with the longest terms and the largest financial exposure.
Section 781 is not a proposal. It is enacted law with a fixed effective date. The November 2026 deadline will arrive whether the FDA publishes its cannabinoid list, whether the enforcement policy clears OMB review, and whether the industry reaches consensus on implementation details.
Operators who begin product audits, testing transitions, and contract reviews now are building a compliance position. Those who wait for clarity may find that clarity arrives after the deadline, not before it.
